Filing Flows › Comparisons › CYRX vs MRVI
Cryoport vs Maravai Lifesciences Holdings: CYRX and MRVI compared
Cryoport is the larger company: $50.2M of revenue in its latest quarter (Q3 2026) against $45.9M for Maravai Lifesciences Holdings (Q3 2026). Cryoport is growing faster (+14% against +10% a year earlier). Cryoport is more profitable, with an operating margin of -17.5% against -45.0%.
Where the money goes: CYRX and MRVI
Cryoport (CYRX) · Q3 2026
Cryoport, Q3 2026: revenue $50.2M (+14% year over year), operating margin -17.5%, net loss $10.9M, operating cash flow $5.2M. The chart follows the revenue to costs, profit and cash.
Maravai Lifesciences Holdings (MRVI) · Q3 2026
Maravai Lifesciences Holdings, Q3 2026: revenue $45.9M (+10% year over year), operating margin -45.0%, net loss $24.0M, operating cash flow $5.0M. The chart follows the revenue to costs, profit and cash.
| Cryoport (CYRX) | Maravai Lifesciences Holdings (MRVI) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $50.2M | $45.9M |
| Revenue growth, Y/Y | +14% | +10% |
| Operating margin | -17.5% | -45.0% |
| Net earnings | −$10.9M | −$24.0M |
| Net margin | -21.6% | -52.3% |
| Operating cash flow | $5.2M | $5.0M |
| Free cash flow | — | $4.5M |
Where the revenue comes from
Cryoport
- Service: $28.6M (57%)
- Product: $21.7M (43%)
Maravai Lifesciences Holdings
- TriLink: $28.4M (62%)
- Cygnus: $17.5M (38%)
Questions
Which is bigger, Cryoport or Maravai Lifesciences Holdings?
Cryoport is the larger company: $50.2M of revenue in its latest quarter (Q3 2026) against $45.9M for Maravai Lifesciences Holdings (Q3 2026).
Is Cryoport or Maravai Lifesciences Holdings growing faster?
Cryoport is growing faster (+14% against +10% a year earlier).
Which is more profitable, Cryoport or Maravai Lifesciences Holdings?
Cryoport is more profitable, with an operating margin of -17.5% against -45.0%.
More: Cryoport earnings · how Cryoport makes money · Maravai Lifesciences Holdings earnings · how Maravai Lifesciences Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.